 NEW HAVEN, Conn., May 20, 2021 GLOBE NEWSWIRE -- Arvinas, Inc. Nasdaq: ARVN, a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on Tuesday, May 25 at 10:00 a.m. ET. 